Coherus Biosciences (CHRS) Stock Statistics & Valuation Metrics

Coherus Biosciences has a market cap or net worth of $161.97M. The enterprise value is ―.

Coherus Biosciences has 120,871,010 shares outstanding. The number of shares has decreased by -2.65% in one year.

Coherus Biosciences’s return on equity (ROE) is -0.22 and return on invested capital (ROIC) is -66.31%.

The current PE Ratio of Coherus Biosciences is ―. Coherus Biosciences’s PEG ratio is -0.05.

In the last 12 months, Coherus Biosciences had revenue of 266.96M and earned 28.51M in profits. Earnings per share was 0.25.

In the last 12 months, operating cash flow was -90.19M and capital expenditures 0.00, giving a free cash flow of -90.19M billion.

Coherus Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―

Coherus Biosciences upcoming earnings date is Mar 17, 2026, After Close (Confirmed).

Coherus Biosciences as a current ratio of 1.21, with Debt / Equity ratio of 2.22%

In the past 12 months, Coherus Biosciences has paid 0.00 in taxes.

Coherus Biosciences EV to EBITDA ratio is 5.43, with an EV/FCF ratio of -16.18.

Coherus Biosciences has $191.66M in cash and marketable securities with $1.95M in debt, giving a net cash position of $189.72M billion.

Gross margin is 37.19%, with operating margin of -41.83%, and net profit margin of 10.68%.

The average price target for Coherus Biosciences is $5.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy